Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
D. Kotani,T. Yoshino,15 Authors,T. Satoh
2025 · DOI: 10.1007/s10147-025-02852-9
International Journal of Clinical Oncology · 0 Citations
TLDR
Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC.